Medigen Vaccine Biologics (6547 TWO) stock market data APIs
NT$48.0445
0.7(1.5%)
as of November 3, 2026
Try our APIs with
free plan!
Medigen Vaccine Biologics Financial Data Overview
Price chart is built with
Anychart
Medigen Vaccine Biologics Corporation, a biotechnology drug company, engages in the research, development, and wholesale of vaccines and biopharmaceuticals, and medical devices in Taiwan. It develops enterovirus A71 vaccine, which is in Phase III clinical trial to treat enterovirus infection with severe complications; and Quadrivalent influenza vaccine, which is in Phase III clinical trial for the treatment of influenza viruses. The company also develops dengue vaccines, which has completed Phase II clinical trial to treat dengue; anti respiratory syncytial virus (RSV), which is in Phase I clinical trial for the prevention of RSV infection; and COVID-19 vaccine, which is in Phase III clinical trial to prevent COVID-19. The company has a collaboration with Charles River Laboratories for the development of next-generation multivalent enterovirus vaccines, enhance global regulatory readiness, and support IND-enabling non-clinical studies. The company was incorporated in 2012 and is headquartered in Zhubei, Taiwan.
Prev. Close
48.0445
Open
48.7445
High
48.7948
Low
47.1069
52 wk Range
33.5-72.2
Market Cap
15 648 M
Shares Outstanding
329 M
Revenue
574 M
EPS
0.07
Beta
0.092
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Medigen Vaccine Biologics (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Medigen Vaccine Biologics data using free add-ons & libraries
Get Medigen Vaccine Biologics Fundamental Data
Medigen Vaccine Biologics Fundamental data includes:
- Net Revenue: 574 M
- EBITDA: -57 845 000
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Medigen Vaccine Biologics Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2026-08-12
- EPS/Forecast: 0.06
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Medigen Vaccine Biologics News
New
Charles River’s (CRL) Vaccine Push Meets A Bumpy Quarter
On August 20, Charles River Laboratories (NYSE:CRL) announced a collaboration with Medigen Vaccine Biologics Corp/MVC to apply next-generation sequencing to MVC's new multivalent enterovirus vaccine p...
Does Charles River (CRL)–Medigen Vaccine Work Sharpen the Case for Its Complex Biologics Edge?
Earlier this week, Medigen Vaccine Biologics Corp. announced a collaboration with Charles River Laboratories International to characterize and validate the virus seed bank for its next-generation mult...
Charles River Laboratories and Medigen Vaccine Biologics Corp Collaborate to Advance New Vaccine Development Programs Through Next Generation Sequencing
Collaboration leverages NGS technologies to accelerate high-quality vaccine development, support global regulatory readiness, and help reduce animal testing WILMINGTON, Mass., August 20, 2026--(BUSIN...
Dynavax (DVAX) Gains as Medigen Rolls Out COVID-19 Vaccine
Shares of Dynavax Technologies Corporation DVAX jumped 14.4% after its Taiwan-based partner Medigen Vaccine Biologics Corporation announced the rollout of its COVID-19 vaccine — MVC-COV1901 — in t...
Get Medigen Vaccine Biologics fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.